X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma: Gearing for 2005 - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 7, 2003

    GSK Pharma: Gearing for 2005

    GlaxoSmithKline Pharmaceuticals Ltd (GSK) is India’s largest pharmaceutical company with a market share of 7%. Globally, its parent, GlaxoSmithKline Plc is the second largest pharma company. Although GSK’s product portfolio boasts of some of the best-known brands in the domestic market, stiff competition and a slump in the domestic market has stunted the company’s revenue growth in recent months. In this context, let us briefly understand GSK’s business structure and its strategy in view of the implementation of product patents post 2005.

    Business structure…
    GSK’s business can be classified into pharma (80% of FY03 revenues), agrivet farm care (AFC) (9%), qualigens fine chem (QFC) (6%) and exports (5%). In the pharma business, GSK’s products enjoy leadership position in the dermatologicals, corticosteriods and thyroid preparation segments. GSK registered an 8% growth in this segment in FY03. The company’s core products continued to record double-digit growth. This apart, augmentin and vaccines range of products also continued to gain market share. In the AFC segment (animal health products), GSK has presence in the cattle, poultry, aquaculture, canine, equine and sheep segment. A large customer coverage and distribution network has helped the company register a 3.6% growth (FY03) despite a slump in domestic market demand.

    In the QFC business (laboratory chemicals), Glaxo enjoys market leadership with a share of 27%. In this segment, the company has presence in diagnostics, laboratory glassware and other laboratory requirements like filter paper, disinfectants, dispowares and distilleries. Although revenues from this segment declined by 4.6% in FY03, this segment made a turnaround of sorts by recording a 9.6% growth in 1HFY04. As far as exports business is concerned, GSK generates revenues by acting as an outsourcing base for its parent. However, with the reduction in requirement of Ranitidine base from the parent, exports have been impacted. Exports declined by 21.8% in FY03 and by a further 47% in 1HFY04.

    Financials…

    Financial overview...
      1HFY03 1HFY04 Growth (%) FY02 FY03 Growth (%)
    Revenues (Rs m) 5,390 5,603 4% 10,103 10,473 4%
    Operating profits (Rs m) 969 1246 29% 1046 1737 66%
    OPM (%) 18.0 22.2   10.4 16.6  
    Net Profits (Rs m) 636 999 57% 440 981 123%
    NPM (%) 11.8 17.8   4.4 9.4  

    Despite tough market conditions in view of the VAT fiasco and general slowdown in the industry, GSK has managed to record a modest growth in the topline. Moreover, benefits of the restructuring exercise undertaken by the company and focus on core brands have started to accrue. Resultantly, GSK was able to double its bottomline. Even during 1HFY04, although the topline grew by a modest 4%, net profits increased by a strong 57%. (For a more detailed analysis of 1HFY04 results click here)

    Gearing for 2005…
    Recognizing the growth potential in the domestic market post 2005, GSK has devised a strategy to take advantage of the same. GSK has targeted a topline growth rate at a little higher than the industry average and a bottomline growth that is faster than the topline growth. Most importantly, the company has decided to make gradual launches of new products. On an average, GSK plans to launch three products per annum. On the operations front, the company devised a strategy to improve its sales force efficiency by 50% during the 2001-05 period. This apart, GSK also plans to make a foray in the high margin chronic areas of CNS and diabetes. The above initiatives are expected to help the company in preparing for the post 2005 product patent regime and take advantage of its parent’s strong product portfolio.

    At Rs 449, GSK is trading at a P/E of 17x its annualized 1HFY04 earnings. Limited exposure in high-margin lifestyle segments of CVS, diabetes and CNS segments and the company’s high exposure to DPCO remains a cause for concern. However, in view of the impending implementation of product patent, the strategy adopted by the company for preparing itself for the same, its market leadership position and access to parent’s strong product portfolio, we remain positive about the long-term prospects of the company.

     

     

    Equitymaster requests your view! Post a comment on "GSK Pharma: Gearing for 2005 ". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK PHARMA SHARE PRICE


    Aug 23, 2017 (Close)

    TRACK GSK PHARMA

    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK PHARMA - ADCOCK INGRAM COMPARISON

    Compare Company With Charts

    COMPARE GSK PHARMA WITH

    MARKET STATS